Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities

被引：1
作者：
West, Howard [1 ,2 ]
Akhade, Amol [3 ,4 ]
Gyawali, Bishal [5 ,6 ,7 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA
[2] AccessHope, Los Angeles, CA USA
[3] Nair Hosp & Topiwala Natl Med Coll Mumbai, Dept Med Oncol, Mumbai, Maharashtra, India
[4] Suyog Canc Clin, Mumbai, Maharashtra, India
[5] Queens Univ, Dept Oncol, Kingston, ON, Canada
[6] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada
[7] Queens Univ, Div Canc Care & Epidemiol, Kingston, ON, Canada
来源：
JCO GLOBAL ONCOLOGY | 2023年 / 9卷
关键词：
D O I：
10.1200/GO.23.00344
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 10 条
[1]   Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial [J].
Herbst, Roy S. ;
Wu, Yi-Long ;
John, Thomas ;
Grohe, Christian ;
Majem, Margarita ;
Wang, Jie ;
Kato, Terufumi ;
Goldman, Jonathan W. ;
Laktionov, Konstantin ;
Kim, Sang-We ;
Yu, Chong-Jen ;
Vu, Huu Vinh ;
Lu, Shun ;
Lee, Kye Young ;
Mukhametshina, Guzel ;
Akewanlop, Charuwan ;
de Marinis, Filippo ;
Bonanno, Laura ;
Domine, Manuel ;
Shepherd, Frances A. ;
Urban, Damien ;
Huang, Xiangning ;
Bolanos, Ana ;
Stachowiak, Marta ;
Tsuboi, Masahiro .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) :1830-+
[2]   AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations [J].
Lu, Shun ;
Dong, Xiaorong ;
Jian, Hong ;
Chen, Jianhua ;
Chen, Gongyan ;
Sun, Yuping ;
Ji, Yinghua ;
Wang, Ziping ;
Shi, Jianhua ;
Lu, Junguo ;
Chen, Shaoshui ;
Lv, Dongqing ;
Zhang, Guojun ;
Liu, Chunling ;
Li, Juan ;
Yu, Xinmin ;
Lin, Zhong ;
Yu, Zhuang ;
Wang, Zhehai ;
Cui, Jiuwei ;
Xu, Xingxiang ;
Fang, Jian ;
Feng, Jifeng ;
Xu, Zhi ;
Ma, Rui ;
Hu, Jie ;
Yang, Nong ;
Zhou, Xiangdong ;
Wu, Xiaohong ;
Hu, Chengping ;
Zhang, Zhihong ;
Lu, You ;
Hu, Yanping ;
Jiang, Liyan ;
Wang, Qiming ;
Guo, Renhua ;
Zhou, Jianying ;
Li, Baolan ;
Hu, Chunhong ;
Tong, Wancheng ;
Zhang, Helong ;
Ma, Lin ;
Chen, Yuan ;
Jie, Zhijun ;
Yao, Yu ;
Zhang, Longzhen ;
Jie, Weng ;
Li, Weidong ;
Xiong, Jianping ;
Ye, Xianwei .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) :3162-+
[3]   Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China [J].
Luo, Zhenhuan ;
Gyawali, Bishal ;
Han, Sheng ;
Shi, Luwen ;
Guan, Xiaodong ;
Wagner, Anita Katharina .
SEMINARS IN ONCOLOGY, 2021, 48 (02) :141-144
[4]  
National Comprehensive Cancer Network, NCCN GUID NONSM CELL
[5]   Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [J].
Ramalingam, S. S. ;
Vansteenkiste, J. ;
Planchard, D. ;
Cho, B. C. ;
Gray, J. E. ;
Ohe, Y. ;
Zhou, C. ;
Reungwetwattana, T. ;
Cheng, Y. ;
Chewaskulyong, B. ;
Shah, R. ;
Cobo, M. ;
Lee, K. H. ;
Cheema, P. ;
Tiseo, M. ;
John, T. ;
Lin, M-C ;
Imamura, F. ;
Kurata, T. ;
Todd, A. ;
Hodge, R. ;
Saggese, M. ;
Rukazenkov, Y. ;
Soria, J-C ;
Boyer, Michael ;
Lee, Chee ;
Hughes, Brett ;
O'Byrne, Kenneth ;
Briggs, Peter ;
Milward, Michael ;
John, Thomas ;
Demedts, Ingel ;
Vansteenkiste, Johan ;
Bustin, Frederique ;
Barrios, Carlos Henrique ;
Timcheva, Constanta ;
Butts, Charles ;
Goss, Glenwood ;
Juergens, Rosalyn ;
Leighl, Natasha ;
Cheng, Susanna ;
Burkes, Ronald ;
Zhou, Caicun ;
Zhang, Helong ;
Shu, Yongqian ;
Cheng, Ying ;
Zhou, Qing ;
Li, Wei ;
Feng, Guosheng ;
He, Yong .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) :41-50
[6]   Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].
Soria, J. -C. ;
Ohe, Y. ;
Vansteenkiste, J. ;
Reungwetwattana, T. ;
Chewaskulyong, B. ;
Lee, K. H. ;
Dechaphunkul, A. ;
Imamura, F. ;
Nogami, N. ;
Kurata, T. ;
Okamoto, I. ;
Zhou, C. ;
Cho, B. C. ;
Cheng, Y. ;
Cho, E. K. ;
Voon, P. J. ;
Planchard, D. ;
Su, W. -C. ;
Gray, J. E. ;
Lee, S. -M. ;
Hodge, R. ;
Marotti, M. ;
Rukazenkov, Y. ;
Ramalingam, S. S. ;
Boyer, Michael ;
Lee, Chee ;
Hughes, Brett ;
O'Byrne, Kenneth ;
Briggs, Peter ;
Milward, Michael ;
John, Thomas ;
Demedts, Ingel ;
Vansteenkiste, Johan ;
Bustin, Frederique ;
Barrios, Carlos Henrique ;
Timcheva, Constanta ;
Butts, Charles ;
Goss, Glenwood ;
Juergens, Rosalyn ;
Leighl, Natasha ;
Cheng, Susanna ;
Burkes, Ronald ;
Zhou, Caicun ;
Zhang, Helong ;
Shu, Yongqian ;
Cheng, Ying ;
Zhou, Qing ;
Li, Wei ;
Feng, Guosheng ;
He, Yong .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :113-125
[7]   Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC [J].
Tsuboi, Masahiro ;
Herbst, Roy S. ;
John, Thomas ;
Kato, Terufumi ;
Majem, Margarita ;
Grohe, Christian ;
Wang, Jie ;
Goldman, Jonathan W. ;
Lu, Shun ;
Su, Wu-Chou ;
de Marinis, Filippo ;
Shepherd, Frances A. ;
Lee, Ki Hyeong ;
Le, Nhieu Thi ;
Dechaphunkul, Arunee ;
Kowalski, Dariusz ;
Poole, Lynne ;
Bolanos, Ana ;
Rukazenkov, Yuri ;
Wu, Yi-Long .
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02) :137-147
[8]   Osimertinib as adjuvant therapy in patients (pts) with stage IBIIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA [J].
Tsuboi, Masahiro ;
John, Thomas ;
Grohe, Christian ;
Majem, Margarita ;
Goldman, Jonathan Wade ;
Kim, Sang-We ;
Marmol, Dominika ;
Rukazenkov, Yuri ;
Wu, Yi-Long .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
[9]   Why Not Adore ADAURA? - The Trial We Need vs the Trial We Got [J].
West, Howard ;
Gyawali, Bishal .
JAMA ONCOLOGY, 2021, 7 (05) :677-678
[10]   Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials [J].
Zhao, Pengfei ;
Zhen, Hongchao ;
Zhao, Hong ;
Zhao, Lei ;
Cao, Bangwei .
BMC CANCER, 2022, 22 (01)
1